KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash from Financing Activities (2016 - 2025)

Eli Lilly (LLY) has disclosed Cash from Financing Activities for 17 consecutive years, with -$2.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 1176.63% year-over-year to -$2.9 billion, compared with a TTM value of -$2.2 billion through Dec 2025, down 279.92%, and an annual FY2025 reading of -$2.2 billion, down 279.92% over the prior year.
  • Cash from Financing Activities was -$2.9 billion for Q4 2025 at Eli Lilly, down from $531.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $3.5 billion in Q4 2023 and bottomed at -$2.9 billion in Q4 2025.
  • Average Cash from Financing Activities over 5 years is -$351.2 million, with a median of -$387.2 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 543.21% in 2025, while the deepest fall reached 1176.63% in 2025.
  • Year by year, Cash from Financing Activities stood at -$1.5 billion in 2021, then grew by 25.23% to -$1.1 billion in 2022, then surged by 410.59% to $3.5 billion in 2023, then crashed by 106.36% to -$225.5 million in 2024, then plummeted by 1176.63% to -$2.9 billion in 2025.
  • Business Quant data shows Cash from Financing Activities for LLY at -$2.9 billion in Q4 2025, $531.0 million in Q3 2025, and -$1.2 billion in Q2 2025.